Although immune checkpoint blockade in AML has not proven beneficial, [136,137,138] there may still be additional effects in combining CAR T cells and immune checkpoint blockage (PD-1, CTLA-4, etc.)that will improve T cell persistence and anti-tumor efficacy [47]. The gene discussed is CTLA4; the disease is neoplasm.